Lawmakers’ letter to FDA targets trials at China’s military hospitals, studies in Xinjiang

In a letter to FDA Commissioner Rob Califf, a bipartisan group of House members is pressing the agency for stricter oversight of U.S. biopharmas’ interactions with the Chinese military as they conduct clinical trials in China.

BioCentury reported last month that the House Select Committee on the Chinese Communist Party was seeking to create public pressure on companies that market drugs in the U.S. to stop conducting trials at sites associated with the People’s Liberation Army (PLA), as well as disengagement from institutions in Xinjiang...